Literature DB >> 12597311

Work, social, and family disabilities of subjects with anxiety and depression.

Barbara L Kennedy1, Ying Lin, John J Schwab.   

Abstract

BACKGROUND: Functional impairment scales are increasingly used to evaluate subjects with a variety of mental disorders.
METHODS: We evaluated the work, social, and family disabilities of 228 subjects with 6 common anxiety and depressive disorders, as assessed by the Sheehan Disability Scale (major depression, panic disorder, generalized anxiety disorder, social phobia, obsessive-compulsive disorder, and mixed anxiety and depression).
RESULTS: Subjects in the 6 diagnostic groups had significantly higher work, social, and family disability scores than control subjects, with the exception of the social phobia and panic disorder subjects' scores for family disability. Those with depressive disorders tended to have significantly higher family disability scores than the anxiety disorder subjects.
CONCLUSION: Subjects with both anxiety and depressive disorders from primary care clinics and from chronic psychiatric and medical populations need further evaluation and treatment of the disabilities to decrease the personal, family, and economic burdens of these disorders.

Entities:  

Mesh:

Year:  2002        PMID: 12597311

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  10 in total

1.  Italian neurologists' perception on cognitive symptoms in major depressive disorder.

Authors:  G Neri; C Serrati; P Zolo; N Cataldo; C Ripellino
Journal:  Neurol Sci       Date:  2016-05-07       Impact factor: 3.307

2.  Development of the Global Disability Scale (Glo.Di.S): preliminary results.

Authors:  Konstantinos N Fountoulakis; Eirini Lekka; Evangelia Kouidi; Ioanna Chouvarda; Asterios Deligiannis; Nickolaos Maglaveras
Journal:  Ann Gen Psychiatry       Date:  2012-05-17       Impact factor: 3.455

3.  Prevalence and its correlates of anxiety disorders from India's National Mental Health Survey 2016.

Authors:  Narayana Manjunatha; Pavithra Jayasankar; Satish Suhas; Girish N Rao; Gururaj Gopalkrishna; Mathew Varghese; Vivek Benegal
Journal:  Indian J Psychiatry       Date:  2022-03-24       Impact factor: 2.983

Review 4.  Patient-reported outcomes in obsessive-compulsive disorder.

Authors:  Mythily Subramaniam; Pauline Soh; Clarissa Ong; Lee Seng Esmond Seow; Louisa Picco; Janhavi Ajit Vaingankar; Siow Ann Chong
Journal:  Dialogues Clin Neurosci       Date:  2014-06       Impact factor: 5.986

5.  Functional Impairment and Quality of Life in Patients with Obsessive Compulsive Disorder.

Authors:  Puspita Sahoo; Rati Ranjan Sethy; Daya Ram
Journal:  Indian J Psychol Med       Date:  2017 Nov-Dec

6.  Cognitive Dysfunction in Asian Patients with Depression (CogDAD): A Cross-Sectional Study.

Authors:  Srisurapanont Manit; Mok Yee Ming; Yang Yen Kuang; Chan Herng-Nieng; Della Constantine D; Zainal Nor Zuraida; Jambunathan Stephen; Amir Nurmiati; Kalita Pranabi
Journal:  Clin Pract Epidemiol Ment Health       Date:  2017-10-31

7.  Outcomes and Correlates of Major Depression in 11 Disaster Studies Using Consistent Methods.

Authors:  Carol S North; David Baron
Journal:  Behav Sci (Basel)       Date:  2021-01-01

8.  Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder.

Authors:  Jean Endicott; Henrik Svedsäter; Julie C Locklear
Journal:  Neuropsychiatr Dis Treat       Date:  2012-07-11       Impact factor: 2.570

9.  Disability and comorbidity: diagnoses and symptoms associated with disability in a clinical population with panic disorder.

Authors:  Caroline A Bonham; Eberhard Uhlenhuth
Journal:  Psychiatry J       Date:  2014-03-02

10.  Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.

Authors:  Lene Hammer-Helmich; Josep Maria Haro; Bengt Jönsson; Audrey Tanguy Melac; Sylvie Di Nicola; Julien Chollet; Dominique Milea; Benoît Rive; Delphine Saragoussi
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-09       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.